New Era for Women's Health: Cyclana Bio's £5M Funding Drives Tissue-Level Drug Innovation
October 22, 2025, 9:38 pm
Cyclana Bio, a cutting-edge Cambridge biotech, has closed a substantial £5 million pre-seed funding round. Co-led by NfX and Eka VC, this capital injection fuels a transformative mission. The company pioneers tissue-level drug discovery, tackling chronic inflammatory diseases like endometriosis. Their innovative platform leverages AI and physiologically relevant models derived from menstrual fluid donations. This approach uncovers novel drug targets by focusing on extracellular matrix dysregulation—a critical, often ignored, mechanism. The funding will accelerate platform development, expand research pipelines, and drive a fundamental shift in women's health therapeutics, aiming to bridge the critical gender health gap in medicine. It's a bold step towards redefining treatment paradigms for underserved conditions.
Cyclana Bio secured £5 million in pre-seed funding. This significant capital injection signals a new chapter for women's health. NfX and Eka VC co-led the round. Cocoa VC, Wilbe, and key angel investors also participated. This funding empowers Cyclana Bio to revolutionize drug discovery for chronic inflammatory diseases.
Endometriosis impacts millions globally. One in ten women worldwide suffer. It causes chronic pain, severe inflammation, and often infertility. This debilitating disease remains poorly understood. Research efforts are historically insufficient. Current treatments fall short. They rarely address underlying biological causes. Many patients find no effective relief. A new approach is desperately needed.
Cyclana Bio is changing the paradigm. They employ a fundamentally new strategy. Their focus is whole-tissue disease modeling. This integrates with AI-driven data analysis. The goal is identifying druggable targets. They seek novel biomarkers. These discoveries occur at the tissue level. Disease truly emerges there. This marks a departure from traditional methods.
A key scientific breakthrough guides Cyclana's work. They identified the extracellular matrix (ECM) as critical. ECM dysregulation drives endometriosis pathology. It causes inflammation. It leads to tissue dysfunction. Most past drug development ignored this. It focused on intracellular pathways instead. Cyclana targets cell-ECM interactions. This unlocks previously inaccessible therapeutic opportunities. This novel focus promises more effective therapies.
Cyclana's models are unique. They are built from menstrual fluid donations. These come from an ongoing observational clinical trial. This methodology recreates functional disease environments. It occurs right in the lab. This supports early biomarker discovery. It also facilitates novel treatment target identification. This approach benefits endometriosis patients. It extends to other chronic inflammatory diseases. Many share similar tissue-level mechanisms. This methodology stands as a testament to their innovative spirit.
The £5 million funding fuels ambitious plans. Cyclana Bio will expand its research pipeline. They will scale their pioneering tissue-level platform. This allows addressing more diseases. Many disproportionately affect women. These conditions are often overlooked by traditional biomedical research. The funding accelerates their mission. It pushes the boundaries of women's health research.
Cyclana Bio champions women's health. Their mission extends beyond a single disease. They aim to close the gender health gap. They seek to propel women to the forefront of drug discovery. Therapies will be developed differently. The basic science begins at the tissue level. Patients are central to their model. This reflects a commitment to consumer-centric innovation. It redefines healthcare priorities.
The company envisions a broader transformation. Their goal is not just new treatments. They aim to change biomedical discovery itself. Starting with women's health addresses a major unmet medical need. This path offers a dual benefit. It cures debilitating diseases for women. It also sets a stage for understanding chronic illness broadly. This foundational shift could redefine medicine globally.
Dr. Léa Wenger leads as CEO and Co-Founder. Prof. Kevin Chalut serves as CSO and Co-Founder. Their combined expertise drives Cyclana Bio's vision. They guide the company's scientific breakthroughs. Their leadership pushes for a patient-centric future. They build a robust pipeline. New treatments are on the horizon. Their dedication underscores the firm's potential.
Cyclana Bio stands poised for immense impact. Their tissue-level platform offers significant promise. It targets complex chronic diseases effectively. It provides a blueprint for future drug development. This firm is not just developing drugs. It is creating a new framework. The future of women's health research looks brighter. Novel treatments are now closer than ever. This represents a significant leap forward in medical science.
Cyclana Bio secured £5 million in pre-seed funding. This significant capital injection signals a new chapter for women's health. NfX and Eka VC co-led the round. Cocoa VC, Wilbe, and key angel investors also participated. This funding empowers Cyclana Bio to revolutionize drug discovery for chronic inflammatory diseases.
Endometriosis impacts millions globally. One in ten women worldwide suffer. It causes chronic pain, severe inflammation, and often infertility. This debilitating disease remains poorly understood. Research efforts are historically insufficient. Current treatments fall short. They rarely address underlying biological causes. Many patients find no effective relief. A new approach is desperately needed.
Cyclana Bio is changing the paradigm. They employ a fundamentally new strategy. Their focus is whole-tissue disease modeling. This integrates with AI-driven data analysis. The goal is identifying druggable targets. They seek novel biomarkers. These discoveries occur at the tissue level. Disease truly emerges there. This marks a departure from traditional methods.
A key scientific breakthrough guides Cyclana's work. They identified the extracellular matrix (ECM) as critical. ECM dysregulation drives endometriosis pathology. It causes inflammation. It leads to tissue dysfunction. Most past drug development ignored this. It focused on intracellular pathways instead. Cyclana targets cell-ECM interactions. This unlocks previously inaccessible therapeutic opportunities. This novel focus promises more effective therapies.
Cyclana's models are unique. They are built from menstrual fluid donations. These come from an ongoing observational clinical trial. This methodology recreates functional disease environments. It occurs right in the lab. This supports early biomarker discovery. It also facilitates novel treatment target identification. This approach benefits endometriosis patients. It extends to other chronic inflammatory diseases. Many share similar tissue-level mechanisms. This methodology stands as a testament to their innovative spirit.
The £5 million funding fuels ambitious plans. Cyclana Bio will expand its research pipeline. They will scale their pioneering tissue-level platform. This allows addressing more diseases. Many disproportionately affect women. These conditions are often overlooked by traditional biomedical research. The funding accelerates their mission. It pushes the boundaries of women's health research.
Cyclana Bio champions women's health. Their mission extends beyond a single disease. They aim to close the gender health gap. They seek to propel women to the forefront of drug discovery. Therapies will be developed differently. The basic science begins at the tissue level. Patients are central to their model. This reflects a commitment to consumer-centric innovation. It redefines healthcare priorities.
The company envisions a broader transformation. Their goal is not just new treatments. They aim to change biomedical discovery itself. Starting with women's health addresses a major unmet medical need. This path offers a dual benefit. It cures debilitating diseases for women. It also sets a stage for understanding chronic illness broadly. This foundational shift could redefine medicine globally.
Dr. Léa Wenger leads as CEO and Co-Founder. Prof. Kevin Chalut serves as CSO and Co-Founder. Their combined expertise drives Cyclana Bio's vision. They guide the company's scientific breakthroughs. Their leadership pushes for a patient-centric future. They build a robust pipeline. New treatments are on the horizon. Their dedication underscores the firm's potential.
Cyclana Bio stands poised for immense impact. Their tissue-level platform offers significant promise. It targets complex chronic diseases effectively. It provides a blueprint for future drug development. This firm is not just developing drugs. It is creating a new framework. The future of women's health research looks brighter. Novel treatments are now closer than ever. This represents a significant leap forward in medical science.